Drug Profile
Research programme: neuroprotective PARP inhibitors - Astellas Pharma
Alternative Names: FR 257516; FR 261529; FR247304Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Pyridines; Quinazolinones
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological disorders (Prevention) in Japan
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 15 Feb 2005 A preclinical study has been added to the Neurological disorders pharmacodynamics section